Fredun Pharmaceuticals Ltd.

As of June 30, 2026, Fredun Pharmaceuticals Ltd. has 16.54M shares outstanding.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 14.88M in revenue per employee across its workforce of 498.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Fredun Pharmaceuticals Ltd. recorded 146.86M in income tax expense. That works out to an effective tax rate of 25.10, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 585.08M, leaving 438.22M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Fredun Pharmaceuticals Ltd. generated 7.42B in revenue and converted that into 438.22M in net income, yielding earnings per share of 27.46. EBITDA reached 1.10B, while operating income came in at 998.92M.

Over the twelve months ended June 30, 2026, Fredun Pharmaceuticals Ltd. posted a gross margin of 25.36, reflecting its pricing power and cost economics. The operating margin of 13.47 and net profit margin of 5.91 provide insight into operational efficiency.

Fredun Pharmaceuticals Ltd.'s most recent stock split took place on July 16, 2026 with a 1:3 split ratio.